Advanced Search

Journal of Traditional Chinese Medicine >

2024 , Vol. 44 >Issue 1: 54 - 62

DOI: https://doi.org/10.19852/j.cnki.jtcm.20231110.002

Original articles

Formulation, characterization and in vivo and in vitro evaluation of aloe-emodin-loaded solid dispersions for dissolution enhancement

  • Xiuyan LI ,
  • Yuting LUO ,
  • Jinhui WANG ,
  • Zhimin DU
Expand
  • 1 Key Laboratory of Basic and Application Research of Beiyao, Heilongjiang University of Chinese Medicine, Ministry of Education, Harbin 150040, China
    2 College of Pharmacy, Harbin Medical University, Harbin 150081, China
    3 Institute of Clinical Pharmacology, the Second Affliated Hospital of Harbin Medical University (University Key aboratory of Drug Research, Heilongjiang Province), Harbin 150086, China; Department of Clinical Pharmacology College of Pharmacy, Harbin Medical University, Harbin 150081, China; State Key Laboratory of Quality Research in Chinese Medicines, Macau University of Science and Technology, Macau 999078, China; College of Pharmacy, Harbin Medical University, Harbin 150081, China

Received date: 2022-02-23

  Accepted date: 2023-07-20

  Online published: 2023-11-10

Fold

Abstract

OBJECTIVE: To prepare aloe-emodin solid dispersion (AE-SD) and determine the metabolic process of AE and AE-SD in vivo.

METHODS: AE-SD was prepared viasolvent evaporation or solvent melting using PEG-6000 and PVP-K30 as carriers. Thermogravimetric analysis, X-ray diffraction spectroscopy, differential scanning calorimetry, Fourier transform infrared spectroscopy and scanning electron microscopy were used to identify the physical state of AE-SD. Optimal prescriptions were screened viathe dissolution degree determination method. Using Phoenix software, AE suspension and AE-SD were subjected to a pharmacokinetic comparison study analyzing the alteration of behavior in vivo after AE was prepared as a solid dispersion. Acute toxicity was assessed in mice, and the physiological toxicity was used as the determination criterion for toxicity.

RESULTS: AE-SD showed that AE existed in the carrier in an amorphous state. Compared with polyethylene glycol, polyvinylpyrrolidone (PVP) inhibited AE crystallization, causing the drug to transform from a dense crystalline state to an amorphous form and increasing the degree of drug dispersion. Therefore, it was more suitable as a carrier material for AE-SD. The addition of poloxamer (POL) was more beneficial to the stability of solid dispersions and could reduce the amount of PVP. The dissolution test confirmed that the optimal ratio of AE to the composite vector AE-PVP-POL was 1：2：2, and its dissolution effect was also optimal. Based on the pharmacokinetic comparison, the drug absorption was faster and quickly reached the peak of blood drug concentration in AE-SD compared to AE, the Cmax of AE-SD was greater than that of AE, and t1/2 and mean residence time of AE-SD were less than AE. The results showed that the drug metabolism in AE-SD was better, and the residence time was shorter. The toxicology study showed that both AE and AE-SD had no toxicity.

CONCLUSION: This paper established that the solubility of the drug could be increased after preparing a solid dispersion, as demonstrated by in vitro dissolution experiments. In vivo pharmacokinetics studies confirmed that AE-SD could improve the bioavailability of AE in vivo, providing a new concept for the research and development of AE preparations.

Key words： aloe-emodin; solid dispersion; solvent evaporation; drug liberation; pharmacokinetics

Cite this article

Xiuyan LI , Yuting LUO , Jinhui WANG , Zhimin DU . Formulation, characterization and in vivo and in vitro evaluation of aloe-emodin-loaded solid dispersions for dissolution enhancement[J]. Journal of Traditional Chinese Medicine, 2024 , 44(1) : 54 -62 . DOI: 10.19852/j.cnki.jtcm.20231110.002

References

1. Yu Y, Liu H, Yang D, et al. Aloe-emodin attenuates myocardial infarction and apoptosis via up-regulating mir-133 expression. Pharmacol Res 2019; 146: 104315.
2. Zhao W, Yuan Y, Feng B, et al. Aloe-emodin relieves zidovudine-induced injury in neonatal rat ventricular myocytes by regulating the p90rsk/p-bad/bcl-2 signaling pathway. Environ Toxicol Pharmacol 2021; 81: 103540.
3. Shang H, Guo J, Wang P, et al. Design, synthesis and anti-inflammatory evaluation of aloe-emodin derivatives as potential modulators of AKT, NF-κB and JNK signaling pathways. Eur J Med Chem 2022; 238: 114511.
4. Tang X, Zhang Y, Liu X, et al. Aloe-emodin derivative produces anti-atherosclerosis effect by reinforcing ambra1-mediated endothelial autophagy. Eur J Pharmacol 2022; 916: 174641.
5. Yu Y, Liu H, Yang D, et al. Aloe-emodin attenuates myocardial infarction and apoptosis via up-regulating mir-133 expression. Pharmacol Res 2019; 146: 104315.
6. Su ZL, Hang PZ, Hu J, et al. Aloe-emodin exerts cholesterol-lowering effects by inhibiting proprotein convertase subtilisin/kexin type 9 in hyperlipidemic rats. Acta Pharmacol Sin 2020; 41: 1085-92.
7. Ji H, Liu Y, He F, An R, Du Z. LC-MS based urinary metabolomics study of the intervention effect of aloe-emodin on hyperlipidemia rats. J Pharm Biomed Anal 2018; 156: 104-15.
8. Chen Y, Feng B, Yuan Y, et al. Aloe emodin reduces cardiac inflammation induced by a high-fat diet through the tlr 4 signaling pathway. Mediators Inflamm 2020; 2020: 6318520.
9. Chen R, Wang S, Zhang J, Chen M, Wang Y. Aloe-emodin loaded solid lipid nanoparticles: formulation design and in vitro anti-cancer study. Drug Deliv 2015; 22: 666-74.
10. Stringaro A, Serra S, Gori A, et al. Peptide-mediated targeted delivery of aloe-emodin as anticancer drug. Molecules 2022; 27: 4615.
11. LaFountaine JS, Prasad LK, Miller DA, et al. Mucoadhesive amorphous solid dispersions for sustained release of poorly water soluble drugs. Eur J Pharm Biopharm 2017; 113: 157-67.
12. Shaker MA, Elbadawy HM, Shaker MA. Improved solubility, dissolution, and oral bioavailability for atorvastatin-pluronic? solid dispersions. Int J Pharm 2020; 574: 118891.
13. Nair AR, Lakshman YD, Anand VSK, Sree KSN, Bhat K, Dengale SJ. Overview of extensively employed polymeric carriers in solid dispersion technology. AAPS Pharm Sci Tech 2020; 21: 309.
14. Rosiak N, Wdowiak K, Tykarska E, Cielecka-Piontek J. Amorphous solid dispersion of hesperidin with polymer excipients for enhanced apparent solubility as a more effective approach to the treatment of civilization diseases. Int J Mol Sci 2022; 23: 15198.
15. Zhu W, Fan W, Zhang X, Gao M. Sustained-release solid dispersion of high-melting-point and insoluble resveratrol prepared through hot melt extrusion to improve its solubility and bioavailability. Molecules 2021; 2: 4982.
16. Kaur A, Bansal AK. Optimization of particle properties of nanocrystalline solid dispersion based dry powder for inhalation of voriconazole. J Pharm Sci 2022; 111: 2592-605.
17. Kline D, Ritruthai V, Babajanian S, et al. Quantitative analysis of aloins and aloin-emodin in aloe vera raw materials and finished products using high-performance liquid chromatography: single-laboratory validation, first action 2016.09. J AOAC Int 2017; 100: 661-70.
18. Sharma N, Singh S. Central composite designed ezetimibe solid dispersion for dissolution enhancement: synthesis and in vitro evaluation. Ther Deliv 2019; 10: 643-58.
19. Annepogu H, Ahad HA, Nayakanti D. Determining the best poloxamer carrier for thiocolchicoside solid dispersions. Turk J Pharm Sci 2020; 17: 372-80.
20. She Rufeng. Development and evaluation of chlorphenidine hydrochloride solid dispersion. Beijing: Chinese Academy of Agricultural Sciences, 2018: 1-63.
21. Sakamoto A, Sugano K. Dissolution kinetics of nifedipine-ionizable polymer amorphous solid dispersion: comparison between bicarbonate and phosphate buffers. Pharm Res 2021; 38: 2119-27.
22. Yu CP, Shia CS, Lin HJ, et al. Analysis of the pharmacokinetics and metabolism of aloe-emodin following intravenous and oral administrations in rats. Biomed Chromatogr 2016; 30: 1641-7.
Options
Outlines

/

〈 〉